Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at ...
Insider Monkey

Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class’ Potential of Cancer Treatment

Erasca Inc. (NASDAQ:ERAS) is one of the 11 Stocks With 3x-5x Returns This Year. Erasca has seen its share prices soar by 390 percent year-to-date, as investors sought to increase their exposure in the ...
Hosted on MSN

Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors

Erasca Inc. (NASDAQ:ERAS) is one of the stocks under $10 to buy now. Earlier on June 2, Erasca announced that the US FDA had cleared its Investigational New Drug/IND application for ERAS-4001. This ...